SG11202012729YA - Bispecific anti-psma x anti-cd28 antibodies and uses thereof - Google Patents
Bispecific anti-psma x anti-cd28 antibodies and uses thereofInfo
- Publication number
- SG11202012729YA SG11202012729YA SG11202012729YA SG11202012729YA SG11202012729YA SG 11202012729Y A SG11202012729Y A SG 11202012729YA SG 11202012729Y A SG11202012729Y A SG 11202012729YA SG 11202012729Y A SG11202012729Y A SG 11202012729YA SG 11202012729Y A SG11202012729Y A SG 11202012729YA
- Authority
- SG
- Singapore
- Prior art keywords
- psma
- antibodies
- bispecific
- bispecific anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862688227P | 2018-06-21 | 2018-06-21 | |
US201862781930P | 2018-12-19 | 2018-12-19 | |
US201862781980P | 2018-12-19 | 2018-12-19 | |
US201962815878P | 2019-03-08 | 2019-03-08 | |
PCT/US2019/038460 WO2019246514A1 (en) | 2018-06-21 | 2019-06-21 | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012729YA true SG11202012729YA (en) | 2021-01-28 |
Family
ID=67297279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012729YA SG11202012729YA (en) | 2018-06-21 | 2019-06-21 | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (3) | US11548947B2 (en) |
EP (1) | EP3810282A1 (en) |
JP (1) | JP2021527431A (en) |
KR (1) | KR20210023982A (en) |
CN (1) | CN112351820A (en) |
AU (1) | AU2019290198A1 (en) |
BR (1) | BR112020025926A2 (en) |
CA (1) | CA3104098A1 (en) |
CL (1) | CL2020003285A1 (en) |
IL (1) | IL279354A (en) |
MA (1) | MA52970A (en) |
MX (1) | MX2020013804A (en) |
PH (1) | PH12020552116A1 (en) |
SG (1) | SG11202012729YA (en) |
WO (1) | WO2019246514A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016535013A (en) | 2013-10-18 | 2016-11-10 | ドイチェス クレブスフォルシュンクスツェントルム | Labeled inhibitor of prostate specific membrane antigen (PSMA), imaging agent for the treatment of prostate cancer and its use as a medicament |
US20230098279A1 (en) * | 2020-02-18 | 2023-03-30 | Endocyte, Inc. | Method of treating psma-expressing cancers |
KR102607909B1 (en) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | Anti-CD28 composition |
CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
IL301037A (en) * | 2020-09-18 | 2023-05-01 | Regeneron Pharma | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
JP2023547507A (en) * | 2020-11-03 | 2023-11-10 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | Target cell-restricted and co-stimulatory bispecific and bivalent anti-CD28 antibody |
TW202242121A (en) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | Use of cd8-targeted viral vectors |
EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
TW202321457A (en) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | Use of cd4-targeted viral vectors |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023164510A1 (en) * | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
WO2023170474A1 (en) | 2022-03-07 | 2023-09-14 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
US20230287146A1 (en) | 2022-03-14 | 2023-09-14 | LamKap Bio gamma AG | BISPECIFIC GPC3xCD28 AND GPC3xCD3 ANTIBODIES AND THEIR COMBINATION FOR TARGETED KILLING OF GPC3 POSITIVE MALIGNANT CELLS |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
TW202405015A (en) * | 2022-04-11 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Antigen-binding molecules specifically binding to psma and cd28 and their pharmaceutical uses |
WO2024018069A1 (en) | 2022-07-22 | 2024-01-25 | Philogen S.P.A | Anti-cd28 antibodies |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024030453A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
CN117844748A (en) * | 2022-09-30 | 2024-04-09 | 北京昌平实验室 | Identification, in vitro amplification and application method of tumor antigen specific memory CD8T cells |
WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
CA2598522A1 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
ATE537190T1 (en) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR |
ES2603559T5 (en) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Mouse common light chain |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20160154B1 (en) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof |
HRP20220133T8 (en) | 2015-09-23 | 2022-05-13 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
EP3192810A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
EP3484516A4 (en) * | 2016-07-14 | 2020-03-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
PT3515487T (en) | 2016-09-23 | 2023-08-24 | Regeneron Pharma | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
KR102520731B1 (en) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind to STEAP2 and CD3, and uses thereof |
US20220185910A1 (en) * | 2018-06-18 | 2022-06-16 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
EA202191580A1 (en) * | 2018-12-19 | 2021-11-01 | Ридженерон Фармасьютикалз, Инк. | SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION |
SG11202105948TA (en) * | 2018-12-19 | 2021-07-29 | Regeneron Pharma | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
MX2021011500A (en) * | 2019-03-22 | 2021-10-22 | Regeneron Pharma | EGFR x CD28 MULTISPECIFIC ANTIBODIES. |
IL301037A (en) * | 2020-09-18 | 2023-05-01 | Regeneron Pharma | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
-
2019
- 2019-06-21 JP JP2020570940A patent/JP2021527431A/en active Pending
- 2019-06-21 CN CN201980041082.5A patent/CN112351820A/en active Pending
- 2019-06-21 US US16/448,462 patent/US11548947B2/en active Active
- 2019-06-21 WO PCT/US2019/038460 patent/WO2019246514A1/en active Application Filing
- 2019-06-21 EP EP19740131.8A patent/EP3810282A1/en active Pending
- 2019-06-21 MA MA052970A patent/MA52970A/en unknown
- 2019-06-21 MX MX2020013804A patent/MX2020013804A/en unknown
- 2019-06-21 BR BR112020025926-8A patent/BR112020025926A2/en unknown
- 2019-06-21 KR KR1020217000650A patent/KR20210023982A/en unknown
- 2019-06-21 AU AU2019290198A patent/AU2019290198A1/en active Pending
- 2019-06-21 SG SG11202012729YA patent/SG11202012729YA/en unknown
- 2019-06-21 CA CA3104098A patent/CA3104098A1/en active Pending
-
2020
- 2020-12-10 PH PH12020552116A patent/PH12020552116A1/en unknown
- 2020-12-10 IL IL279354A patent/IL279354A/en unknown
- 2020-12-17 CL CL2020003285A patent/CL2020003285A1/en unknown
-
2022
- 2022-12-07 US US18/077,139 patent/US20230303696A1/en active Pending
- 2022-12-07 US US18/077,137 patent/US20230272078A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3104098A1 (en) | 2019-12-26 |
US11548947B2 (en) | 2023-01-10 |
BR112020025926A2 (en) | 2021-03-23 |
IL279354A (en) | 2021-01-31 |
US20190389951A1 (en) | 2019-12-26 |
PH12020552116A1 (en) | 2021-07-19 |
KR20210023982A (en) | 2021-03-04 |
US20230303696A1 (en) | 2023-09-28 |
US20230272078A1 (en) | 2023-08-31 |
WO2019246514A1 (en) | 2019-12-26 |
EP3810282A1 (en) | 2021-04-28 |
JP2021527431A (en) | 2021-10-14 |
CN112351820A (en) | 2021-02-09 |
MX2020013804A (en) | 2021-03-31 |
AU2019290198A1 (en) | 2021-01-14 |
CL2020003285A1 (en) | 2021-05-28 |
MA52970A (en) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279354A (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
IL279974A (en) | Bispecific anti-bcma x anti-cd3 antibodies and uses thereof | |
IL283493A (en) | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof | |
IL283945A (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof | |
IL283530A (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
EP3889179A4 (en) | Bispecific antibody and use thereof | |
IL278846A (en) | Anti-cd3 antibodies and uses thereof | |
HK1258304A1 (en) | Optimized anti-cd3 bispecific antibodies and uses thereof | |
IL279053A (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use | |
IL278844A (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
IL279455A (en) | Anti-pd-1 antibodies and uses thereof | |
EP3527590A4 (en) | Anti-egfr and anti-cd3 bispecific antibody and applications thereof | |
IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
EP3661555A4 (en) | Bispecific antibodies and uses thereof | |
EP3819313A4 (en) | Bispecific antibody and use thereof | |
IL278862A (en) | Monospecific and multispecifc anti-tmeff2 antibodies and their uses | |
EP3833693A4 (en) | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
IL274121A (en) | Bispecific antibodies binding alk-1 and bmpr-2 | |
IL278926A (en) | Antibodies specific for cd3 and uses thereof | |
EP3733713A4 (en) | Bispecific antibody and uses thereof | |
IL276675A (en) | Anti-pd-1 antibodies and uses thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
IL280281A (en) | Anti-cd40 antibodies and uses thereof | |
IL283180A (en) | Anti-pd-1 antibodies and uses thereof | |
EP3917579A4 (en) | Bispecific antibodies and uses thereof |